Option chain shows key data for TransCode Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for TransCode Therapeutics.

TransCode Therapeutics (NASDAQ:RNAZ) Stock, Option Chain

TransCode Therapeutics

TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMBI

AVXL

CERO

CGTX

EZPW

INVO

LGVN

LUXH

NUZE

PHIO

RNAZ

TIVC

VTVT

YIBO

Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket

Why Does Coca-Cola Taste Different In Other Countries?

Earnings

Eurozone

Commodities

Intraday Update

ADIL

AZTR

CLRB

FEIM

JAGX

Gold Moves Higher; Coca-Cola Increases FY24 Forecast

vaccine-4892059

Transcode Therapeutics shares are trading lower by 62% during Tuesday&#39;s session. The company announced pricing of its public offering.

Why Transcode Therapeutics (RNAZ) Stock Is Down 60%

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics Inc

WIIM

AKYA

Akoya Biosciences shares are trading lower after the company reported worse-than-expected Q3 financial results.

Wells Fargo analyst Steven Cahall maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Overweight and raises the price target from $116 to $138.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Walt Disney, Raises Price Target to $138

Raymond James analyst Felix Boeschen downgrades Landstar System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTR#NASDAQ">LSTR</a>) from Outperform to Market Perform.

Downgrades

LSTR

Raymond James Downgrades Landstar System to Market Perform

IPower shares are trading lower after the company reported worse-than-expected Q1 financial results.

LGCY

Legacy Education shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

Solidion Technology shares are trading higher. The company yesterday announced it is allocating a portion of its excess cash reserves to Bitcoin.

Raymond James analyst Olivia Tong upgrades Sally Beauty Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBH#NYSE">SBH</a>) from Underperform to Market Perform.

Upgrades

Raymond James Upgrades Sally Beauty Holdings to Market Perform

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer discretionary sector.
<h3 class="wp-block-heading">Guess?, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>)</h3>
<ul>
<li>Dividend Yield: 7.08%</li>
<li>Small Cap Consumer Research analyst Eric Beder reiterated a Buy rating with a price target of $29 on Oct. 24. This analyst has an accuracy rate of 60%.</li>
<li>Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating and cut the price target from $26 to $21 on Aug. 29. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Aug. 28, Guess reported worse-than-expected second-quarter adjusted EPS results and cut its FY25 adjusted EPS guidance below estimates. Additionally, the company issued third-quarter adjusted EPS guidance below estimates.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1">latest GES news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="820" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15034542/image-166.png" alt="" class="wp-image-649740" style="width:702px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15034542/image-166.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15034542/image-166-300x268.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15034542/image-166-768x687.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">Bloomin&#8217; Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>)</h3>
<ul>
<li>Dividend Yield: 7.15%</li>
<li>Raymond James analyst Brian Vaccaro downgraded the stock from Outperform to Market Perform on Nov. 11. This analyst has an accuracy rate of 82%.</li>
<li>Piper Sandler analyst Brian Mullan maintained a Neutral rating and slashed the price target from $20 to $16 on Nov. 11. This analyst has an accuracy rate of 76%.</li>
<li>Recent News: On Nov. 8, the company reported third-quarter adjusted earnings per share of 21 cents, beating the street view of 20 cents. Quarterly revenues of $1.038 billion (down 3.8%) missed the analyst consensus of $1.042 billion.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1">latest BLMN news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="792" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15034652/image-167.png" alt="" class="wp-image-649747" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15034652/image-167.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15034652/image-167-300x263.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15034652/image-167-768x674.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>)</h3>
<ul>
<li>Dividend Yield: 10.74%</li>
<li>JP Morgan analyst Matthew Boss downgraded the stock from Neutral to Underweight with a price target of $19 on Aug. 29. This analyst has an accuracy rate of 66%.</li>
<li>Baird analyst Mark Altschwager maintained an Outperform rating and cut the price target from $27 to $25 on Aug. 29. This analyst has an accuracy rate of 71%.</li>
<li>Recent News: On Nov. 13, the company's board declared a regular quarterly dividend of 50 cents per share on its common stock.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1">trend in KSS stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15034826/image-168.png" alt="" class="wp-image-649749" style="width:783px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15034826/image-168.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15034826/image-168-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15034826/image-168-768x707.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41971544/jim-cramer-recommends-microsoft-praises-american-water-works-for-being-consistent">Jim Cramer Recommends Microsoft, Praises American Water Works For Being &#8216;Consistent&#8217;</a></li>
</ul>

Dividends

BLMN

Wall Street's Most Accurate Analysts Spotlight On 3 Consumer Stocks With Over 7% Dividend Yields

Bernstein analyst Laurent Yoon maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Outperform and raises the price target from $115 to $120.

Bernstein Maintains Outperform on Walt Disney, Raises Price Target to $120

Samsung Electronics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) announces plans to <a target="_blank" href="https://news.samsung.com/global/samsung-electronics-to-buy-back-krw-10-trillion-in-stock" rel="noreferrer noopener">repurchase </a>shares worth 10 trillion won (~$7.17B) as part of its strategy to boost shareholder value.
The Board of Directors approved the buyback program, which will be executed in phases over the next 12 months.
Samsung Electronics will repurchase 3 trillion won in shares from November 18, 2024, to February 17, 2025, as the first phase of its new buyback plan.
The buyback includes 50.14 million common shares and 6.91 million preferred shares, all of which will be canceled to enhance shareholder value.
The remaining portion of the share buyback program will be executed in phases, with timing and methods determined by the Board of Directors.
Samsung Electronics posted a net income of $7.1 billion for the third quarter, with $2.8 billion in profit from its chip division, boosted by strong AI and data center demand. However, delays in NVIDIA&#8217;s AI chip certification allowed competitors SK Hynix and Micron to gain an edge in high-bandwidth memory sales. Mobile chip sales dipped due to inventory adjustments.
Image credits: Arcansel on Shutterstock
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41509305/nvidia-supplier-sk-hynix-reports-record-breaking-quarterly-profit-as-ai-demand-drives-7-revenue-" rel="noreferrer noopener">Nvidia Supplier SK Hynix Reports Record-Breaking Quarterly Profit As AI Demand Drives 7% Revenue Surge</a>

Equities

Buybacks

SSNLF

Samsung Plans Massive $7.2B Stock Buyback: Details

EV giant Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) on Thursday announced the company&#8217;s new charging equipment called the V4 cabinet aimed at increasing charging speed and enabling sufficient charging infrastructure for the company&#8217;s upcoming <a href="https://www.benzinga.com/topic/tesla-semi">Tesla Semi</a> vehicle slated to enter production in 2026.
What Happened: The V4 Cabinet, Tesla said, supports 400V-1000V vehicle architectures and is capable of delivering up to 500kW for cars and 1.2 MW for the company&#8217;s upcoming Semi. It powers 8 posts and twice the stalls per cabinet. 
&#8220;Our first sites with V4 Cabinets are going into permitting now. First openings in 2025,&#8221; Tesla said in a post on X. 
While Tesla launched its V4 posts last year, it was still using a V3 cabinet, limiting power output.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://t.co/I1TqfSpiyD">https://t.co/I1TqfSpiyD</a>
&mdash; Tesla Charging (@TeslaCharging) <a href="https://twitter.com/TeslaCharging/status/1857133221538148638?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;There&#8217;s great engineering behind the V4 system that enables faster charging speeds, lower deployment costs, more efficient power conversion, and higher power density. These benefits for Tesla Semi customers will be a key part of scaling electric trucking,&#8221; Senior Manager for Semi Truck Engineering Dan Priestly said in a post on X.
The new V4 cabinet can also enable charging the company&#8217;s Cybertruck 30% faster, the company said.
Max de Zegher, Tesla&#8217;s Director of Charging, North America, highlighted the efficiency improvements of the new V4 Cabinet, saying, &#8220;Even some of the small incremental improvements matter. V4 Cabinet has a 2% efficiency improvement. Superchargers already deliver over 5 TWh/year, 100 GWh/year in waste heat that can be saved.&#8221;
This is equivalent to the annual electricity usage of over 9,000 households in the U.S. on average, according to data from the U.S. Energy Information Administration.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Posts can peak up to 500kW for cars, but we need less than 1MW across 8 posts to deliver maximum power to cars 99% of the time. No more DC busbar between cabinets. Power comes from a single V4 cabinet to 8 stalls. Easier to install, cheaper, more reliable. Even some of the… <a href="https://t.co/Tou0tiaBaL">https://t.co/Tou0tiaBaL</a>
&mdash; Max de Zegher (@MdeZegher) <a href="https://twitter.com/MdeZegher/status/1857149749880885641?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: As of the end of the third quarter, Tesla had 6,706 supercharger stations around the globe and 62,421 connectors. 
During Tesla&#8217;s annual shareholder meeting in June, Tesla CEO&nbsp;Elon Musk&nbsp;slammed rumors of the&nbsp;<a href="https://www.benzinga.com/news/24/05/38757383/elon-musk-announces-500m-investment-in-teslas-supercharger-network-expansion-in-2024" target="_blank" rel="noreferrer noopener">death of its supercharger network&nbsp;</a>following a <a href="https://www.benzinga.com/news/24/10/41200538/tesla-supercharger-network-growth-slows-sequentially-ev-giant-adds-2-800-stalls-in-q3">major layoff in April </a>as &#8220;greatly exaggerated.&#8221; Tesla will invest $500 million in expanding the network this year, Musk then said.
Tesla&#8217;s company-wide layoffs in April impacted <a href="https://www.benzinga.com/news/24/05/38846223/elon-musk-fired-supercharger-chief-rebecca-tinucci-and-her-entire-team-after-she-refused-to-lay-off" target="_blank" rel="noreferrer noopener">500 members of the supercharging team</a>&nbsp;and&nbsp;Rebecca Tinucci, Tesla&#8217;s then Senior Director of Charging Infrastructure, left the company.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/partner/fintech/24/11/41939694/the-power-of-leverage-global-broker-octa-lays-out-the-ins-and-outs-of-this-trading-tool-for-trade" target="_blank" rel="noreferrer noopener">Ford Cuts Capri, Explorer EV Output Due To ‘Significantly Lower Than Expected Demand' After Pausing F-150 Lightning Production</a></li>
</ul>
Photo courtesy: Tesla

Tech

TSLA

Tesla's V4 Supercharger Cabinet Can Charge Cybertruck 30% Faster, Recharge Tesla Semi And Save Annual Electricity Usage Of Over 9000 Homes

Wells Fargo analyst Mike Mayo maintains Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) with a Equal-Weight and raises the price target from $54 to $62.

ZION

Wells Fargo Maintains Equal-Weight on Zions Bancorp, Raises Price Target to $62

B of A Securities analyst Jay Cohen maintains Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) with a Buy and lowers the price target from $143 to $136.

ACGL

B of A Securities Maintains Buy on Arch Capital Group, Lowers Price Target to $136

WiSA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WISA#NASDAQ">WISA</a>) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(0.67) by 107.46 percent. The company reported quarterly sales of $1.17 million which beat the analyst consensus estimate of $650.00 thousand by 80.31 percent. This is a 52.41 percent increase over sales of $769.00 thousand the same period last year.

Earnings Beats

Earnings Misses

WISA

WiSA Technologies Q3 2024 GAAP EPS $(1.39) Misses $(0.67) Estimate, Sales $1.17M Beat $650.00K Estimate

B of A Securities analyst Jessica Ehrlich maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Buy and raises the price target from $120 to $140.

B of A Securities Maintains Buy on Walt Disney, Raises Price Target to $140

HC Wainwright &amp; Co. analyst Scott Buck maintains Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) with a Buy and lowers the price target from $7 to $5.

DPRO

HC Wainwright & Co. Maintains Buy on Draganfly, Lowers Price Target to $5

BENF

Beneficient shares are trading higher after the company reported a year-over-year increase in Q2 revenue results.

Wells Fargo analyst Mike Mayo maintains U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) with a Overweight and raises the price target from $60 to $62.

Wells Fargo Maintains Overweight on U.S. Bancorp, Raises Price Target to $62

B of A Securities analyst Vivek Arya maintains Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Buy and lowers the price target from $220 to $210.

AMAT

B of A Securities Maintains Buy on Applied Mat, Lowers Price Target to $210

GREE

Greenidge Generation Holdings shares are trading higher after a New York Supreme Court judge rejected the New York State Department of Environmental Conservation's action to deny the company's application for renewal of a Title V Air Permit.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
TransCode Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnaz-stock-quote/">RNAZ</a>) just reported results for the second quarter of 2024.<ul><li>TransCode Therapeutics reported earnings per share of -74 cents. This was below the analyst estimate for EPS of -58 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/rnaz-stock-earnings-transcode-therapeutics-for-q2-of-2024/">RNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q2 2024

TransCode Therapeutics secures $2M grant for lead candidate

TransCode Therapeutics (RNAZ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar ...

Buy Rating for TransCode Therapeutics Backed by NIH Grant and Promising Treatment Efficacy

Warning: RNAZ is at high risk of performing badly

TransCode Therapeutics (RNAZ) announced that the Safety Review Committee, SRC, monitoring its Phase 1 clinical trial has unanimously approved openi...

Transcode announces SRC approval of second cohort in Phase 1 TTX-MC138 trial

TransCode Therapeutics gets Nasdaq extension to regain compliance

TransCode Therapeutics (RNAZ) announced that it has received notice from The Nasdaq Stock Market that the Nasdaq Hearings Panel before which TransC...

Transcode Therapeutics announces Nasdaq extension to regain compliance

Transcode Therapeutics, Inc. ( ($RNAZ) ) has released its Q3 earnings. Here is a breakdown of the information Transcode Therapeutics, Inc. presente...

Transcode Therapeutics Reports Increased Losses Amid Funding Challenges

Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on TransCode Therapeutics (RNAZ – Research Report) and keeping the price target a...

TransCode Therapeutics: Buy Rating Backed by Strategic Focus and Promising Phase 1 Study

Biotech

Financing

Press Releases

General

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

Health Care

TransCode Therapeutics, Inc. Announces Closing of Public Offering

TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate's Preclinical Efficacy Against Metastatic Cancer

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology

TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

Comments

TransCode Therapeutics

TransCode Therapeutics (RNAZ) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga